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Mycophenolate mofetil for the treatment
of autoimmune diseases: hype or hope?
Like other drugs before it, mycophenolate
mofetil (MMF)was introduced into the treatment of
“autoimmune diseases” after successful use in trans-
plantation medicine for prevention or treatment of
graft rejection. Since physicians caring for patients
with autoimmune diseases are increasingly using
MMF, it is time to question the rationale behind its
use.
By inhibition of purine nucleotide synthesis
MMFappears to act preferentially on activated lym-
phocytes, which are thought to play a major role in
autoimmune processes. Mycophenolic acid, the ac-
tive metabolite of MMF, selectively inhibits inosine
5’-monophosphate dehydrogenase, a key enzyme of
the purine de novo synthesis pathway of guanosine
nucleotides [1]. There are two pathways for guano-
sineproduction,thedenovopathwayand the salvage
pathway. In activated lymphocytes the de novo path-
way is dominant. Blocking the de novo pathway
throughmycophenolic acid is thought to be respon-
sible for the reduced proliferation ofT lymphocytes
in vitro, and possibly explains immunosuppressive
effects of MMF in vivo.
MMF has indeed proven effective in suppress-
ing immune reactions,more specifically alloimmune
reactions inpatients after solidorgan transplantation
[2]. This suggests the strong probability of an in-
hibitory effect ofMMF not only on alloimmune re-
actionsbut alsoonautoimmune reactions,becauseT
lymphocytes are potentially involved in both.These
and other considerations may have been the reasons
behind the use ofMMF in the treatment of autoim-
mune diseases (AD).But more important than these
theoretical considerations is current knowledge of
the clinical effects of MMF in patients withAD.
The largest body of evidence exists for its use in
the treatment of lupus nephritis; this has been re-
viewed by Moore and Derry [3]. Randomised trials
and cohort studies showed thatMMF is as effective,
orevenmoreeffective,thancyclophosphamide in in-
duction of remission in these patients.This is amile-
stoneinthetherapyoflupusnephritis,becauseMMF,
in contrast to cyclophosphamide, does not cause
amenorrhoea and infertility in the often young fe-
male lupuspatients.However,therearestill concerns
about the design and patient selection of published
trials, and in selected cases some physicians may still
prefer to give cyclophosphamide precedence over
MMF.For indications other than lupus nephritis no
randomised controlled trials have been published so
far, and the evidence derives from uncontrolled
prospective trials or from retrospective case series.
Response to MMF has been most frequently re-
ported in patients with systemic sclerosis (SSC),
myositis and antineutrophil cytoplasmatic antibod-
ies (ANCA)associatedvasculitides.Manyofthosese-
ries are reviewed by Bandelier and colleagues in this
issue of the journal [4]. In the same article they de-
scribe their own impressive results with the use of
MMF in patients with AD, and show, by retrospec-
tive chart review, that from 11 pre-treated patients
with various connective tissue diseases at least 10 re-
sponded to therapy withMMF.
What do we learn from these reports? When
shouldwe treat our patientswithMMF?Despite the
accumulation of promising data on the use ofMMF
in patients with AD, real evidence exists only for lu-
pus nephritis. There is hope that MMF could be of
value in patients with SSC, a disease with very lim-
ited therapeutic options, and the same goes for the
inflammatory muscle diseases. Here data on steroid
sparing immunosuppressive drugs, or on regimens
for refractory patients, are largely lacking.
Until we receive results from prospective con-
trolled trials for drugs (as in this case MMF) for po-
tential new indications, we cannot distinguish be-
tween real hope for our patients andmere“hype” for
a new drug. For MMF the first trials are under way.
For patients with small vessel vasculitides the EU-
VAS study group compares MMF with cyclophos-
phamide for induction therapy (www.vasculitis.org).
In addition, several trials are actively recruiting and,
amongstother indications,MMFisbeing studied for
patients with autoimmune hepatitis, SSC and adult
Schoenlein-Hennoch purpura (http://clinicaltri-
als.gov/).
Finally, there is hope that these trials will con-
firm the first positive reports on the use of MMF in
patients withAD.
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